TY - JOUR
T1 - Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia
T2 - a retrospective study on behalf of the chronic malignancies working party of the EBMT
AU - van Gorkom, Gwendolyn
AU - van Gelder, Michel
AU - Eikema, Dirk-Jan
AU - Blok, Henric-Jan
AU - van Lint, M. T.
AU - Koc, Yener
AU - Ciceri, Fabio
AU - Beelen, Dietrich
AU - Chevallier, Patrice
AU - Selleslag, Dominik
AU - Blaise, Didier
AU - Foa, Roberto
AU - Corradini, Paolo
AU - Castagna, Luca
AU - Moreno, Carol
AU - Solano, Carlos
AU - Muller, Lutz Peter
AU - Tischer, Johanna
AU - Hilgendorf, Inken
AU - Hallek, Michael
AU - Bittenbring, Joerg
AU - Theobald, Matthias
AU - Schetelig, Johannes
AU - Kroger, Nicolaus
AU - CLL Subcomm Chronic Malignancies
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.
AB - Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.
KW - BONE-MARROW-TRANSPLANTATION
KW - MINIMAL RESIDUAL DISEASE
KW - POSTTRANSPLANTATION CYCLOPHOSPHAMIDE
KW - ALLOGENEIC TRANSPLANTATION
KW - EUROPEAN-SOCIETY
KW - DONOR TRANSPLANTATION
KW - BLOOD
KW - CLL
KW - MULTICENTER
KW - SURVIVAL
U2 - 10.1038/s41409-017-0023-2
DO - 10.1038/s41409-017-0023-2
M3 - Article
C2 - 29255169
SN - 0268-3369
VL - 53
SP - 255
EP - 263
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 3
ER -